Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Shanghai Fosun Pharmaceutical (Group) Co's Average Total Inventories for the quarter that ended in Jun. 2026 was $878 Mil. Shanghai Fosun Pharmaceutical (Group) Co's Revenue for the
three
months ended in Jun. 2026 was $1,530 Mil.
Shanghai Fosun Pharmaceutical (Group) Co's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.57.
A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Shanghai Fosun Pharmaceutical (Group) Co's Days Inventory for the
three
months ended in Jun. 2026 was 103.97.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Shanghai Fosun Pharmaceutical (Group) Co's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.88.
Shanghai Fosun Pharmaceutical (Group) Co (OTCPK:SFOSF) Inventory-to-Revenue Explanation
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Shanghai Fosun Pharmaceutical (Group) Co's Days Inventory for the
three
months ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co Inventory-to-Revenue Related Terms
Shanghai Fosun Pharmaceutical (Group) Co Inventory-to-Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co Inventory-to-Revenue Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co Inventory-to-Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Fosun Pharmaceutical (Group) Co's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Shanghai Fosun Pharmaceutical (Group) Co's Inventory-to-Revenue falls into.
Shanghai Fosun Pharmaceutical (Group) Co Inventory-to-Revenue Calculation
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) has a Inventory-to-Revenue of 0.57 as of Jun. 2026. Inventory-to-Sales ratio is the total inventories divided by total sales. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors.
Is Shanghai Fosun Pharmaceutical (Group) Co's Inventory-to-Revenue too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Inventory-to-Revenue is 0.57. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Inventory-to-Revenue compare to ZTS?
Shanghai Fosun Pharmaceutical (Group) Co's Inventory-to-Revenue of 0.57 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory-to-Revenue for a Drug Manufacturers company?
A good Inventory-to-Revenue depends on the Drug Manufacturers industry context. However, Inventory-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory-to-Revenue mean?
A high Inventory-to-Revenue can signal that a stock is expensive relative to its fundamentals. Inventory-to-Sales ratio is the total inventories divided by total sales. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. Shanghai Fosun Pharmaceutical (Group) Co's current Inventory-to-Revenue is 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.39, compared to a current price of $1.93 — trading 19.2% below its estimated fair value. The current Inventory-to-Revenue is 0.57. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 68/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory-to-Revenue calculated?
Inventory-to-Revenue is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SFOSF), the current Inventory-to-Revenue is 0.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued.
The current stock price of $1.93 is trading 19.2% below its estimated GF Value™ of $2.39.
GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.
Key valuation signals for SFOSF:
Inventory-to-Revenue: 0.57
GF Value™: $2.39 vs. price of $1.93 (19.2% below fair value)
No single metric tells the full story. See the SFOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
68GF Score
Get the complete analysis for SFOSF
Inventory-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SFOSF has been successfully added to your 
